---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-273131"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:50:46.354423+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Instil Bio voluntarily pauses enrollment in three clinical trials over manufacturing issues

## Summary
- Voluntary pause in DELTA-1 Phase 2 trial of ITIL-168 for advanced melanoma due to decreased manufacturing success rate causing inability to dose some patients.
- No unexpected safety issues identified in DELTA-1 patients who received ITIL-168; pre-specified safety analysis completed.
- Also paused DELTA-2 Phase 1 trial of ITIL-168 with pembrolizumab and ITIL-306 Phase 1 trial as part of overall manufacturing analysis.
- Company will provide update on manufacturing analysis by early Q1 2023.
- No regulatory agency, including FDA, has notified the company of a clinical hold.

## SEC filing metadata
- accession: 0001193125-22-273131
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000119312522273131/0001193125-22-273131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000119312522273131/d407219d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-273131
- JSON: https://secwatch.observer/filing/0001193125-22-273131.json
- Plain text: https://secwatch.observer/filing/0001193125-22-273131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.